New insights into complement: A mediator of injury and marker of disease activity in systemic lupus erythematosus

Lupus

Volumn 13, Issue 5, 2004, Pages 298-303

  Manzi, Susan ^a,b,d   Ahearn, J M ^a   Salmon, Jane ^c,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d Lupus Center of Excellence   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Complement; Complement activation; Complement receptor 1; Lupus activity; Pregnancy

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4D; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DISEASE ACTIVITY; DISEASE MARKER; FETUS OUTCOME; FETUS WASTAGE; HUMAN; PATHOGENESIS; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 2942715102     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu1016oa     Document Type: Article

References (57)

1. Gatenby PA. The role of complement in the aetiopathogenesis of systemic lupus erythematosus. Autoimmunity 1991; 11: 61-66.
2. Schur PH. Complement and lupus erythematosus. Arthritis Rheum 1982; 25: 793-798.
3. Barilla-LaBarca ML, Atkinson JP. Rheumatic syndromes associated with complement deficiency. Curr Opin Rheumatol 2003; 15: 55-60.
4. Navratil JS, Ahearn JM. Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited. Curr Rheumatol Rep 2000; 2: 32-38.
5. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-324.
6. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Ann Rev Immunol 1998; 16: 545-568.
7. Liu CC, Navratil JS, Sabatine JM, Ahearn JM. Apoptosis, complement and SLE. Curr Dir Autoimmun 2004; 7: 49-86.
8. Barrington R, Zhang M, Fischer M, Carroll MC. The role of complement in inflammation and adaptive immunity. Immunol Rev 2001; 180: 5-15.
9. Vaughan JH, Bayles TB, Favour CB. The response to serum gamma globulin level and complement titer to adrenocorticotropic hormone (ACTH) therapy in lupus erythematosus disseminatus. J Lab Clin Med 1951; 37: 698-702.
10. Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60: 208-217.
11. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359-366.
12. Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1991; 18: 678-685.
13. Ting CK, Hsieh KH. A long-term immunological study of childhood onset systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 45-51.
14. Abrass CK, Nies KM, Louie JS, Border WA, Glassock RJ. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1980; 23: 273-282.
15. Cameron JS, Lessof MH, Ogg CS, Williams BD, Williams DG. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody. Clin Exp Immunol 1976; 25: 418-427.
16. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39: 370-378.
17. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996; 23: 1891-1896.
18. Morrow WJ, Isenberg DA, Todd-Pokropek A, Parry HF, Snaith ML. Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med 1982; 51: 125-138.
19. Kerr LD, Adelsberg BR, Spiera H. Complement activation in systemic lupus erythematosus: a marker of inflammation. J Rheumatol 1986; 13: 313-319.
20. Gawryl MS, Chudwin DS, Langlois PF, Lint TF. The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1988; 31: 188-195.
21. Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 1994; 21: 2239-2241.
22. Valentijn RM, van Overhagen H, Hazevoet HM et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1985; 28: 904-913.
23. Perrin LH, Lambert PH, Miescher PA. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 1975; 56: 165-176.
24. Belmont HM, Hopkins P, Edelson HS et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986; 29: 1085-1089.
25. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992; 35: 1028-1037.
26. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 1985; 312: 1594-1599.
27. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31: 632-641.
28. Kerr LD, Adelsberg BR, Schulman P, Spiera H. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum 1989; 32: 1406-1413.
29. Manzi S, Rairie JE, Carpenter AB et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996; 39: 1178-1188.
30. Nagy G, Brozik M, Varga L et al. Usefulness of detection of complement activation products in evaluating SLE activity. Lupus 2000; 9: 19-25.
31. Porcel JM, Ordi J, Castro-Salomo A et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 1995; 74: 283-288.
32. Senaldi G, Makinde VA, Vergani D, Isenberg DA. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 1988; 47: 913-917.
33. Sturfelt G, Johnson U, Sjoholm AG. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 1985; 14: 184-196.
34. Sturfelt G, Sjoholm AG. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1984; 75: 75-83.
35. Alper CA, Rosen FS, Alper CA, Rosen FS. Studies of the in vivo behavior of human C′3 in normal subjects and patients. J Clin Invest 1967; 46: 2021-2034.
36. Charlesworth JA, Peake PW, Golding J et al. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 153-159.
37. Hunsicker LG, Ruddy S, Carpenter CB et al. Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med 1972; 287: 835-840.
38. Sliwinski AJ, Zvaifler NJ. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol 1972; 11: 21-29.
39. Tsukamoto H, Ueda A, Nagasawa K, Tada Y, Niho Y. Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus. Clin Exp Immunol 1990; 82: 257-261.
40. Hartung K, Baur MP, Coldewey R et al. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest 1992; 90: 1346-1351.
41. Hauptmann G, Tappeiner G, Schifferli JA. Inherited deficiency of the fourth component of human complement. Immunodefic Rev 1988; 1: 3-22.
42. Moulds JM, Warner NB, Arnett FC. Complement component C4A and C4B levels in systemic lupus erythematosus: quantitation in relation to C4 null status and disease activity. J Rheumatol 1993; 20: 443-447.
43. Atkinson JP, Chan AC, Karp DR et al. Origin of the fourth component of complement related Chido and Rodgers blood group antigens. Complement 1988; 5: 65-76.
44. Giles CM, Davies KA, Walport MJ. In vivo and in vitro binding of C4 molecules on red cells: a correlation of numbers of molecules and agglutination. Transfusion 1991; 31: 222-228.
45. Hammond A, Rudge AC, Loizou S, Bowcock SJ, Walport MJ. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic erythematosus and the antiphospholipid syndrome. Arthritis Rheum 1989; 32: 259-264.
46. Davies KA, Peters AM, Beynon HL, Walport MJ. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 1992; 90: 2075-2083.
47. Walport MJ, Lachman PJ. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum 1988; 31: 153-158.
48. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.
49. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum. Reprod. 1994; 9: 1328-1332.
50. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220.
51. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest 2003; 11: 1644-1654.
52. Lockshin MD, Qamar T, Redecha P, Harpel PC. Hypocomplementemia with low Cls-Clr inhibitor complex in systemic lupus erythematosus. Arthritis Rheum 1986; 29: 1467-1472.
53. Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992; 35: 55-61.
54. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31: 632-641.
55. Lockshin MD, Harpel PC, Druzin ML et al. Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient. Arthritis Rheum 1985; 28: 58-66.
56. Buyon JP, Cronstein BN, Morris M, Tanner M, and Weissmann G. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 1986; 81: 194-200.
57. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol 1992; 10: 455-460.